Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deborah J. Wexler MD, MSc Associate Editor

Silvio E. Inzucchi MD Editor-in-Chief

Kathleen M. Dungan MD, MPH Advisory Board

See All Experts

Published in Diabetes and

News · April 11, 2024

ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes

Larger reductions seen in heart failure-related symptoms and physical limitations for patients with HFpEF, type 2 diabetes

HealthDay

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

story of the week

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Diabetes Obes Metab · December 26, 2024
featured

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Obesity · December 26, 2024
featured

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Diabetes Care · December 25, 2024
featured

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Diabetes Care · December 23, 2024

updated
featured

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

J Diabetes Complicat · December 23, 2024
story of the week

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Diabetes Care · December 19, 2024
featured

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Diabetes Obes Metab · December 19, 2024
featured

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Diabetes Care · December 19, 2024
featured

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Diabetes Obes Metab · December 18, 2024
featured

Potential Off-Label Indication of Metformin for Ischaemic Stroke

Diabetes Obes Metab · December 18, 2024
featured

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Diabetes Obes Metab · December 18, 2024

ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes

Further Reading

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Recently Updated